Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton…
In this article, Trinity analyzed existing guidelines and evaluation frameworks for digital health technologies, including mobile health (mHealth) applications, to identify key evidence requirements and areas that should be considered in the clinical assessment of digital health services.
In 2020, Trinity assessed three applications developed to treat Opioid Use Disorders (OUD) (e.g., reSET-O, Connections, DynamiCare) through the lens of ICER conducting a cost-effectiveness evaluation. Only a year later, several more health tech startups have adopted a preventative outlook and seek to address chronic pain with digital health tools (e.g., phone applications) [...]
Written by Tom Rutkowski, Patrick Buck, Kate Watkins, and Cameron Lam
Three digital health technologies have been developed to treat opioid use disorder (OUD). These applications, reSET-O (Pear Therapeutics), Connections (Chess Health) and DynamiCare (DynamiCare Health) [...]
Written by Tom Rutkowski, Jay Galli, and Kate Watkins
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake. Payers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritization [...]